Inventor · disambiguated record
Duncan Brown
Also filed as: BROWN DUNCAN · BROWN DUNCAN PARLEY
20 granted patents·43 pending applications·104 citations·filing 2010–2025
94Inventor score
Files withSIRNA THERAPEUTICS INC22E THERAPEUTICS PLC8DYNE THERAPEUTICS INC6Q-STATE BIOSCIENCES INC4BROWN DUNCAN3
Top patents by PatentIndex Score
63 records- 0193US10793860B2RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (SINA)SIRNA THERAPEUTICS INC·Filed 2019·Granted Oct 6, 2020·5 cites·10 claims
- 0293US9879262B2RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)SIRNA THERAPEUTICS INC·Filed 2016·Granted Jan 30, 2018·12 cites·15 claims
- 0393US8835623B2RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)SIRNA THERAPEUTICS INC·Filed 2013·Granted Sep 16, 2014·15 cites·20 claims
- 0492US9464290B2RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)SIRNA THERAPEUTICS INC·Filed 2015·Granted Oct 11, 2016·11 cites·15 claims
- 0591US8518907B2RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)BROWN DUNCAN·Filed 2011·Granted Aug 27, 2013·16 cites·17 claims
- 0690US10407682B2RNA interference mediated inhibition of hepatitis B Virus (HBV) gene expression using short interfering nucleic acid (siNA)SIRNA THERAPEUTICS INC·Filed 2017·Granted Sep 10, 2019·7 cites·10 claims
- 0789US9850491B2RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)SIRNA THERAPEUTICS INC·Filed 2016·Granted Dec 26, 2017·5 cites·15 claims
- 0888US2024247271A1Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)SIRNA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0987US10729787B2Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moietySIRNA THERAPEUTICS INC·Filed 2018·Granted Aug 4, 2020·2 cites·12 claims
- 1087US9447420B2RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (SINA)SIRNA THERAPEUTICS INC·Filed 2014·Granted Sep 20, 2016·6 cites·39 claims
- 1187US2025066791A1Rna interference mediated inhibition of prolyl hydroxylase domain 2 (phd2) gene expression using short interfering nucleic acid (sina)SIRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1286US10577606B2RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)SIRNA THERAPEUTICS INC·Filed 2017·Granted Mar 3, 2020·2 cites·14 claims
- 1384US9233997B2RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)ASON BRANDON·Filed 2011·Granted Jan 12, 2016·7 cites·11 claims
- 1484US9029341B2RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)BARTZ STEVE·Filed 2011·Granted May 12, 2015·13 cites·15 claims
- 1582US11332745B2RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (SINA)SIRNA THERAPEUTICS INC·Filed 2020·Granted May 17, 2022·1 cites·13 claims
- 1680US11952573B2RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)SIRNA THERAPEUTICS INC·Filed 2022·Granted Apr 9, 2024·0 cites·12 claims
- 1779US2023144623A1Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moietySIRNA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1877US2023030119A1Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)SIRNA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1976US10004814B2Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moietySIRNA THERAPEUTICS INC·Filed 2014·Granted Jun 26, 2018·2 cites·14 claims
- 2072US12435337B2Inhibitors of expression and/or functionE THERAPEUTICS PLC·Filed 2024·Granted Oct 7, 2025·0 cites·19 claims
- 2172US11529428B2Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moietySIRNA THERAPEUTICS INC·Filed 2020·Granted Dec 20, 2022·0 cites·16 claims
- 2272US2025312490A1Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moietySIRNA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2368US2025034563A1Methods and Compositions for ADAR-Mediated EditingKORRO BIO INC·Filed 2022·Application pending·0 cites
- 2468US2024102018A1Oligonucleotide compositions and methods thereofAMYLYX PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2568US2019330639A1Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)SIRNA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2667US2025034564A1Methods and Compositions for ADAR-Mediated EditingKORRO BIO INC·Filed 2022·Application pending·0 cites
- 2767US2024102017A1Oligonucleotide compositions and methods thereofAMYLYX PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2866US10246714B2RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)SIRNA THERAPEUTICS INC·Filed 2017·Granted Apr 2, 2019·0 cites·23 claims
- 2966US2014088937A1Methods of Predicting The Probability of Modulation of Transcript Levels By RNAI CompoundsBROWN DUNCAN·Filed 2013·Application pending·0 cites
- 3066US2025388903A1Methods and Compositions for Adar-Mediated EditingKORRO BIO INC·Filed 2025·Application pending·0 cites
- 3166US2025051766A1Treatment of neurological diseases using modulators of unc13a gene transcriptsHINCKLEY SANDRA·Filed 2022·Application pending·0 cites
- 3265US12152243B2Therapeutic compositions for treating pain via multiple targetsQ STATE BIOSCIENCES INC·Filed 2021·Granted Nov 26, 2024·0 cites·19 claims
- 3365US2024382513A1Muscle targeting complexes and uses thereof for modulation of genes associated with muscle healthDYNE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3465US2023203180A1Muscle targeting complexes and uses thereof for modulation of genes associated with muscle healthDYNE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3564US2025163419A1Therapeutic compositions for treating pain via multiple targetsQUELLTX INC·Filed 2024·Application pending·0 cites
- 3664US2025099603A9Muscle targeting complexes and uses thereof for treating friedreich's ataxiaDYNE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3764US2025257359A1Musk-targeting oligonucleotidesBOLDEN THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3864US2024294921A1Muscle targeting complexes and uses thereof for treating pompe diseaseDYNE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3961US2016298123A1Rna interference mediated inhibition of prolyl hydroxylase domain 2 (phd2) gene expression using short interfering nucleic acid (sina)SIRNA THERAPEUTICS INC·Filed 2015·Application pending·0 cites
- 4060US2025304969A1Inhibitors of expression and/or functionE THERAPEUTICS PLC·Filed 2025·Application pending·0 cites
- 4159US2024110184A1Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophyDYNE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4258US2024352458A1Double stranded nucleic acid compounds inhibiting zpiE THERAPEUTICS PLC·Filed 2024·Application pending·0 cites
- 4357US2024209377A1Therapeutic compositions for treating pain via multiple targetsQ STATE BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 4457US2025368992A1Nucleic acid compoundsE THERAPEUTICS PLC·Filed 2023·Application pending·0 cites
- 4557US2025376680A1Nucleic acid compoundsE THERAPEUTICS PLC·Filed 2023·Application pending·0 cites
- 4657US2025295688A1Compositions and methods of modulating xanthine dehydrogenaseHORIZON THERAPEUTICS IRELAND DAC·Filed 2022·Application pending·0 cites
- 4756US2025388897A1Nucleic acid compoundsE THERAPEUTICS PLC·Filed 2023·Application pending·0 cites
- 4856US2023111147A1Muscle targeting complexes and uses thereof for modulation of genes associated with muscle healthDYNE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4956US2022403389A1Therapeutic oligonucleotide methodsQ STATE BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 5056US2022372489A1Ppm1a inhibitors and methods of using sameQURALIS CORP·Filed 2020·Application pending·0 cites
Showing the top 50 of 63 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Duncan Brown files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →